ALOX15 (Gene)

Organism:

Homo sapiens

Synonyms:12-LOX, 15-LOX, 15-LOX-1, ALOX15, ENTREZ:246, HGNC:433, LOG15, MIM:152392, NM_001140, NP_001131, arachidonate 15-lipoxygenase

Omim:OMIM:152392

Id:ENSG00000161905

Hgnc:HGNC:433

Entrez:246

Ensembl:ENSG00000161905

Description:arachidonate 15-lipoxygenase

This gene encodes a member of the lipoxygenase family of proteins. The encoded enzyme acts on various polyunsaturated fatty acid substrates to generate various bioactive lipid mediators such as eicosanoids, hepoxilins, lipoxins, and other molecules. The encoded enzyme and its reaction products have been shown to regulate inflammation and immunity. Multiple pseudogenes of this gene have been identified in the human genome. [provided by RefSeq, Aug 2017]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ALOX15's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ALOX15.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ALOX15.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ALOX15.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ALOX15.

Results found

Linked to

	Label	Description
	GSE239844 11 V 9 CRIZOTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176403 GSE176404 LSD1 inhibition 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	T62-Spleen Consensus Gene Set (Entity type)	A Gene Set from MoTrPAC
	GSE210682 0 V 3 METHADONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE201309 4 V 2 MATRINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218098 GSE218099 TCF19 knockdown RNA Small Interfering 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE239844 11 V 9 CRIZOTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE176403 GSE176404 LSD1 inhibition 1 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

T62-Spleen Consensus

Gene Set (Entity type)

A Gene Set from MoTrPAC

GSE210682 0 V 3 METHADONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE201309 4 V 2 MATRINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 6 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE218098 GSE218099 TCF19 knockdown RNA Small Interfering 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.